Amendments to the Claims:

This listing of claims will replace all prior versions of claims in the application:

81. (Previously presented) An osteogenic protein comprising one or more polypeptide chains capable of inducing endochondral bone formation when disposed within a matrix and implanted in a mammal, wherein said polypeptide chain is further characterized as having cysteine residues in the same relative positions as the cysteine skeleton sequence:

or a point mutation thereof, wherein said protein or said mutant protein is capable of inducing endochondral bone formation in a mammal, and wherein each X represents any amino acid.

82-87. (Canceled)

88. (Previously presented) A device for implantation in a mammal, comprising:

a biocompatible, in vivo biodegradable matrix defining pores of a dimension sufficient to permit influx, proliferation and differentiation of migratory progenitor cells from the body of said mammal; and

a substantially pure osteogenic protein comprising one or more polypeptide chains capable of inducing endochondral bone formation when disposed within a matrix and implanted in a mammal, wherein said polypeptide chain is further characterized as having cysteine residues in the same relative positions as the cysteine skeleton sequence:

Amendment and Response to Notice to File Missing Parts U.S. Serial No. 10/671,317 Page 4 of 6

or a point mutation thereof, wherein said protein or said mutant protein is capable of inducing endochondral bone formation in a mammal, and wherein each X represents any amino acid.

89-95. (Canceled)

- 96. (Currently amended) A method of inducing endochondral bone formation in a mammal comprising the step of implanting the device of any one of claims 88[[-95]] in said mammal at a locus accessible to migratory progenitor cells of said mammal.
- 97. (Canceled)